Palatin Technologies Inc
F:PTN
Palatin Technologies Inc
EPS (Diluted)
Palatin Technologies Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Palatin Technologies Inc
F:PTN
|
EPS (Diluted)
-$1
|
CAGR 3-Years
30%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-10%
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$0
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-26%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$7
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
-$2
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$38
|
CAGR 3-Years
-19%
|
CAGR 5-Years
16%
|
CAGR 10-Years
29%
|
|
Palatin Technologies Inc
Glance View
Palatin Technologies Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies to address unmet medical needs in various health conditions, particularly in women's health and sexual dysfunction. The company is primarily known for its lead product candidate, Vyleesi (bremelanotide injection), which was approved by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). This groundbreaking therapy offers a novel approach to a condition that has traditionally been underserved, highlighting Palatin’s commitment to improving quality of life for its patients. With a robust pipeline of other potential treatments, the company is positioning itself to be a significant player in the biotech sector. Investors will find Palatin appealing not only for its unique product offerings but also for its strategic partnerships and collaborations that enhance its research capabilities and market reach. The company has established relationships with key healthcare organizations, enabling it to conduct pivotal clinical trials and expand its product visibility. Additionally, leadership at Palatin utilizes a disciplined, value-investing approach, ensuring that resources are allocated wisely towards projects with solid scientific backing and commercial potential. As the company advances its portfolio, it aims to create long-term shareholder value while addressing critical areas of health, making it a compelling opportunity for those looking to invest in the future of biopharmaceutical innovations.
See Also
What is Palatin Technologies Inc's EPS (Diluted)?
EPS (Diluted)
-1.3
USD
Based on the financial report for Dec 31, 2024, Palatin Technologies Inc's EPS (Diluted) amounts to -1.3 USD.
What is Palatin Technologies Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-10%
Over the last year, the EPS (Diluted) growth was 42%. The average annual EPS (Diluted) growth rates for Palatin Technologies Inc have been 30% over the past three years , and -10% over the past ten years .
You don't have any saved screeners yet